50% Dextrose Injection, USP Concentrated Dextrose for Intravenous Administration | Dextrose [Hospira, Inc.] | BioPortfolio

12:48 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

NOTE: This solution is hypertonic — See WARNINGS and PRECAUTIONS .

LifeShield™ Abboject Syringe Fliptop Container

Ansyr™ Plastic Syringe

Ansyr™II Plastic Syringe R only

50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for injection for intravenous injection as a fluid and nutrient replenisher.

Each mL of fluid contains 0.5 g dextrose, hydrous which delivers 3.4 kcal/gram. The solution has an osmolarity of 2.53 mOsmol/mL (calc.), a pH of 4.2 (3.2 to 6.5) and may contain sodium hydroxide and/or hydrochloric acid for pH adjustment.

The solution contains no bacteriostat, antimicrobial agent or added buffer (except for pH adjustment) and is intended only for use as a single-dose injection. When smaller doses are required, the unused portion should be discarded with the entire unit.

Dextrose, USP is chemically designated CHO ∙ HO (D-glucose monohydrate), a hexose sugar freely soluble in water. Dextrose, hydrous has the following structural formula:

Water for Injection, USP is chemically designated HO.

The syringe is molded from a specially formulated polypropylene. Water permeates from inside the container at an extremely slow rate which will have an insignificant effect on solution concentration over the expected shelf life. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the syringe material.

When administered intravenously this solution restores blood glucose levels in hypoglycemia and provides a source of carbohydrate calories.

Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein-sparing action. Dextrose injection undergoes oxidation to carbon dioxide and water.

Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).

Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na) plays a major role in maintaining physiologic equilibrium.

50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels.

The solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. Slow infusion of hypertonic solutions is essential to insure proper utilization of dextrose and avoid production of hyperglycemia.

A concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present, nor in the presence of delirium tremens if the patient is already dehydrated.

Dextrose injection without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.

50% Dextrose Injection is hypertonic and may cause phlebitis and thrombosis at the site of injection.

Significant hyperglycemia and possible hyperosmolar syndrome may result from too rapid administration. The physician should be aware of the symptoms of hyperosmolar syndrome, such as mental confusion and loss of consciousness, especially in patients with chronic uremia and those with known carbohydrate intolerance.

The intravenous administration of this solution can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.

Additives may be incompatible. Consult with pharmacist if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.

The solution should be given slowly, preferably through a small bore needle into a large vein, to minimize venous irritation.

Concentrated dextrose should be administered via central vein only after suitable dilution.

Do not use unless the solution is clear and seal is intact. Discard unused portion.

Electrolyte deficits, particularly in serum potassium and phosphate, may occur during prolonged use of concentrated dextrose solutions. Blood electrolyte monitoring is essential and fluid and electrolyte imbalances should be corrected. Essential vitamins and minerals also should be provided as needed.

To minimize hyperglycemia and consequent glycosuria, it is desirable to monitor blood and urine glucose and if necessary, add insulin.

When a concentrated dextrose infusion is abruptly withdrawn, it is advisable to follow with the administration of 5% or 10% dextrose injection to avoid rebound hypoglycemia.

Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.

Care should be exercised to insure that the needle is well within the lumen of the vein and that extravasation does not occur. If thrombosis should occur during administration, the injection should be stopped and corrective measures instituted.

Concentrated dextrose solutions should not be administered subcutaneously or intramuscularly.

Studies with solutions in polypropylene syringes have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.

Animal reproduction studies have not been conducted with dextrose. It is also not known whether dextrose can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dextrose should be given to a pregnant woman only if clearly needed.

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when 50% Dextrose Injection, USP is administered to a nursing mother.

Hyperosmolar syndrome, resulting from excessively rapid administration of concentrated dextrose may cause mental confusion and/or loss of consciousness.

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

In the event of overhydration or solute overload during therapy, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS and PRECAUTIONS .

Injection of the solution should be made slowly.

The maximum rate at which dextrose can be infused without producing glycosuria is 0.5 g/kg of body weight/hour. About 95% of the dextrose is retained when infused at a rate of 0.8 g/kg/hr.

In insulin-induced hypoglycemia, intravenous injection of 10 to 25 grams of dextrose (20 to 50 mL of 50% dextrose) is usually adequate. Repeated doses and supportive treatment may be required in severe cases. A specimen for blood glucose determination should be taken before injecting the dextrose. In such emergencies, dextrose should be administered promptly without awaiting pretreatment test results.

For total parenteral nutrition 50% Dextrose Injection, USP is administered by slow intravenous infusion (a) after admixture with amino acid solutions via an indwelling catheter with the tip positioned in a large central vein, preferably the superior vena cava, or (b) after dilution with sterile water for injection. Dosage should be adjusted to meet individual patient requirements.

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

The maximum rate of dextrose administration which does not result in glycosuria is the same as cited above.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See CONTRAINDICATIONS .

50% Dextrose Injection, USP is supplied in single-dose containers as follows:

NDC No. Container Size
0409-4902-34 LifeShield Abboject® Unit of Use Syringe with male luer lock adapter and protected needle 25 g in 50 mL
0409-6648-02 Fliptop Vial 25 g in 50 mL
0409-7517-15 Ansyr™ Plastic Syringe 25 g in 50 mL
0409-7517-16 Ansyr™ II Plastic Syringe with syringe and barrel detached 25 g in 50 mL

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

October, 2009

Hospira, Inc., Lake Forest, IL 60045 USA


Abboject is a trademark of the Abbott group of companies.


50 mL Single-dose NDC 0409-7517-15

50% DEXTROSE Injection, USP

25 grams (0.5 g/mL) Rx only

For I.V. use. Usual dosage: See insert. Sterile, nonpyrogenic.2.53 mOsmol/mL (calc.). pH 4.2 (3.2 to 6.5) Hospira

RL-0628 (10/04)

Hospira, Inc., Lake Forest, IL 60045 USA

50 mLNDC 0409-7517-15

50% DEXTROSE Injection, USP

25 grams (0.5 g/mL)


Unit of Use Syringe

LifeShield with male luer lock adapter

Rx only




50 mL Single-doseNDC 0409-7517-16

50% DEXTROSE Injection, USP 25 grams (0.5 g/mL)

Rx only

For I.V. use. Usual dosage: See insert. Sterile, nonpyrogenic.2.53 mOsmol/mL (calc.). pH 4.2 (3.2 to 6.5)


RL-0629 (10/04)

50 mL

NDC 0409-7517-16

50%DEXTROSE Injection, USP

25 grams (0.5 g/mL)


Unit of Use Syringe

LifeShield with male luer lock adapter

Rx only




50 mL Single-doseNDC 0409-4902-34

50% DEXTROSE Inj., USP 25 grams (0.5 g/mL)

For I.V. use. Usual dosage: See insert.Sterile, nonpyrogenic.2.53 mOsmol/mL (calc.)pH 4.2 (3.2 to 6.5)

Rx only


RL-0239 (5/04)

Hospira, Inc., Lake Forest, IL 60045 USA

50 mLNDC 0409-4902-34

50%DEXTROSEInjection, USP

25 grams (0.5 g/mL)


GlassABBOJECT Unit of Use Syringe

with male luer lockadapter and18-Gauge protected needle

Rx only



50 mL Single-dose

50% DextroseInjection, USP

25 grams/50 mL (0.5 g/mL)

Hospira, Inc.Lake Forest, IL 60045 USA


50 mL Single-dose Fliptop Vial

25 Units/NDC 0409-6648-02 Rx only

50% Dextrose Injection, USP

25 grams/50 mL (0.5 g/mL)

Hospira, Inc., Lake Forest, IL 60045 USA


25% DEXTROSE (250 mg/mL)

10 mL Single-dose Rx onlyNDC 0409-1775-10

25% DEXTROSE Injection, USP 2.5 grams (250 mg/mL)

Usual Dosage: For intravenous use. See insert. Sterile,nonpyrogenic.1.39 mOsmol/mL (calc.). pH is 4.5 (3.2 to 6.5).


Hospira, Inc., Lake Forest, IL 60045 USA

RL-0351 (7/04)

10 mLNDC 0409-1775-10

Infant25%DEXTROSEInjection, USP

2.5 g

(250 mg/mL)


Unit of Use Syringe

LifeShield™ with maleluer lock adapter

Rx only






Hospira, Inc.

Active Ingredients


Drugs and Medications [241 Associated Drugs and Medications listed on BioPortfolio]

Haemonetics anticoagulant citrate dextrose solution [haemonetics corporation]

Haemonetics Anticoagulant Citrate Dextrose Solution

Diltiazem hcl [cantrell drug company]

Diltiazem HCl 250 mg in 5% Dextrose 300 mL Bag

Dextrose [baxter healthcare corporation]

5% Dextrose Injection, USP

Morphine sulfate [cantrell drug company]

Morphine Sulfate 1 mg/mL in 5% Dextrose 100 mL Bag

Amiodarone hcl [cantrell drug company]

Amiodarone HCl 900 mg Added to 5% Dextrose 500 mL Bag

Clinical Trials [114 Associated Clinical Trials listed on BioPortfolio]

40% Orally Administered Dextrose Gel is More Effective Than 25% Dextrose

The aim of this study was to evaluate the safe of 40% Dextrose oral administration on blood glucose concentration and to reducing of pain before painful procedures on healthy term neonate ...

Changes in Cytokine Levels After Dextrose Injection in Stage IV Knee Osteoarthritis

Twenty participants with severe arthritis will be enrolled. For the first week participants will either be injected with dextrose or just have fluid withdrawn for testing. The remaining pa...

Ulnar Wrist Pain Treatment With Dextrose Prolotherapy

Participants with wrist pain on the little finger side of the wrist will received either usual care, consisting of ultrasound, specialized massage and stabilization exercises therapy for 6...

Delto-Tricipital Compression Syndrome: Treated With Injection of Dextrose

The posterior antebrachial cutaneous nerve (PACN) can be compressed between the deltoid and triceps, with resultant pain and dysfunction. The active treatment for this study will be injec...

Effects of Hypertonic Dextrose Water Injection for Supraspinatus Tendinosis Patients

Using hypertonic dextrose water for chronic supraspinatus tendonitis and using ultrasound as assessment tool to evaluate the effect of intervention.

PubMed Articles [34 Associated PubMed Articles listed on BioPortfolio]

Comparison of imaged capillary isoelectric focusing and cation exchange chromatography for monitoring dextrose-mediated glycation of monoclonal antibodies in infusion solutions.

Intravenous (IV) infusion of therapeutic proteins typically involves dilution of the formulated product into infusion media such as normal saline or dextrose, 5% m/v in water. We report results from a...

Effects of hypertonic dextrose and paraffin solution as non-antibiotic treatments of clinical endometritis on reproductive performance of high producing dairy cows.

The objective of this study is to compare the reproductive performance of cows affected by clinical endometritis (CE) following treatment with an intrauterine infusion of 50% dextrose solutions (DEX) ...

Hypertonic milk replacers increase gastrointestinal permeability in healthy dairy calves.

Hypertonic milk replacers are commonly used in animal production systems and their effect on the gastrointestinal system of young animals is insufficiently studied. Total lactose inclusion or its part...

Embolization of a Complex Facial Arteriovenous Malformation, Balloon-Assisted Flow Arrest, and Controlled n-BCA Injection with Dextrose Push Technique: 2-Dimensional Operative Video.

N-butyl cyanoacrylate glue (n-BCA, Cerenovus, Irvine, California) is commonly used to treat arteriovenous malformation (AVM). Even though Onyx (ethylene vinyl alcohol, Medtronic, Dublin, Ireland) pres...

Stability of mycophenolate mofetil in polypropylene 5% dextrose infusion bags and chemical compatibility associated with the use of the EQUASHIELD® closed-system transfer device.

Stability studies are necessary in healthcare settings as they facilitate fast, cost-effective and efficient work related to batch manufacturing and availability of supplies. We studied the stability ...

Quick Search


Relevant Topics

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Drugs and Medication Quicklinks

Searches Linking to this Drug Record